Clinico-biologic profile of Langerhans cell histiocytosis: a single institutional study.

Simple item page
dc.contributor.authorNarula, Gen_US
dc.contributor.authorBhagwat, Ren_US
dc.contributor.authorArora, Ben_US
dc.contributor.authorBanavali, Sden_US
dc.contributor.authorPai, Sken_US
dc.contributor.authorNair, Cnen_US
dc.contributor.authorSeth, Ten_US
dc.contributor.authorLaskar, Sen_US
dc.contributor.authorMuckaden, Maen_US
dc.contributor.authorKurkure, Paen_US
dc.contributor.authorParikh, Pmen_US
dc.date.accessioned2009-05-28T07:00:41Z
dc.date.available2009-05-28T07:00:41Z
dc.date.issued2007-07-06en_US
dc.description.abstractCONTEXT: Langerhans cell histiocytosis (LCH) is a rare atypical cellular disorder characterized by clonal proliferation of Langerhans cells leading to myriad clinical presentations and highly variable outcomes. There is a paucity of Indian studies on this subject. AIM: To present the experience of management of LCH at a single institution. SETTINGS AND DESIGN: This is a retrospective observational study of patients with LCH who presented at the Tata Memorial Hospital between January 1987 and December 2002. MATERIALS AND METHODS: Fifty-two patients with LCH were treated in the study period. Due to the long observation period and variability in diagnostic and therapeutic protocols, the patients were risk-stratified based on present criteria. The disease pattern, management approaches and treatment outcomes of patients were recorded. STATISTICAL ANALYSIS USED: Statistical analyses were done using Student's 't' test, test for proportion and survival estimates based on the Kaplan-Meier method. RESULTS: The median age at presentation was 3 years and more than 48% of the patients had Group I disease. Skeleton, skin and lymphoreticular system were the commonly involved organs. Majority (80%) required some form of therapy. The projected overall survival is 63% at 10 years and mean survival is 118 months. Seventeen percent of surviving patients developed long-term sequelae. CONCLUSIONS: The clinico-biologic profile of LCH patients in India is largely similar to international patterns except a higher incidence of lymphoreticular involvement. Majority of the patients respond favorably to therapy and have a good outcome, except a subset of Group I patients who warrant enrollment in clinical trials with innovative therapeutic strategies to improve outcome.en_US
dc.description.affiliationDepartment of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai - 400 012, Maharashtra, India.en_US
dc.identifier.citationNarula G, Bhagwat R, Arora B, Banavali S, Pai S, Nair C, Seth T, Laskar S, Muckaden M, Kurkure P, Parikh P. Clinico-biologic profile of Langerhans cell histiocytosis: a single institutional study. Indian Journal of Cancer. 2007 Jul-Sep; 44(3): 93-8en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/50721
dc.language.isoengen_US
dc.source.urihttps://www.indianjcancer.comen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAntineoplastic Agents --therapeutic useen_US
dc.subject.meshChilden_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshFemaleen_US
dc.subject.meshHistiocytosis, Langerhans-Cell --diagnosisen_US
dc.subject.meshHumansen_US
dc.subject.meshInfanten_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshRadiotherapyen_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshRisk Factorsen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleClinico-biologic profile of Langerhans cell histiocytosis: a single institutional study.en_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Indian Journal of Cancer